Global medical leadership and clinical governance

Directing multi-disciplinary medical organizations across forty international jurisdictions. Specializing in Phase III trial execution, cross-border FDA and EMA regulatory approvals, and strategic health economics advisory for biopharma board appointments.

Institutional Scale

Verified regulatory and pipeline milestones

$2.4B

late-stage pipeline enterprise value

14

global FDA and EMA drug approvals

40+

international trial jurisdictions managed

18

Phase III clinical programs directed

Executive Scope

Clinical execution and corporate strategy

Translational medicine requires rigorous oversight of complex Phase III protocols while aligning clinical development pathways with enterprise M&A advisory and market-access strategy across major international jurisdictions.

By establishing unified cross-border regulatory governance across FDA, EMA, and PMDA frameworks, multi-continent trial organizations achieve accelerated approvals without compromising empirical precision or data integrity.

Clinical Governance

Governance protects global enterprise value

Empirical precision and structured clinical governance protect patient safety while maximizing long-term commercial viability, aligning clinical development with enterprise risk mitigation for biopharma board governance.

Initiate Executive Inquiry

Confidential search and nomination inquiries

Direct communication channel for retained executive search partners, venture capital operating directors, and corporate nomination committees evaluating C-suite and board-level appointments.